Severe Cytokine Release Syndrome and Hemophagocytic Lymphohistiocytosis (HLH)-Like Syndrome Following Administration of Combined Brentuximab Vedotin and Nivolumab for Recurrent Classical Hodgkin Lymphoma: A Case Report

References

• Cheson BD, Bartlett NL, LaPlant B, et al. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (Accru): a multicentre, single-arm, Phase 2 trial. Lancet Haematol. 2020;7(11):e808–e815. doi:10.1016/S2352-3026(20)30275-1
   PubMed Web of Science ®Google Scholar
• Yasenchak CA, Bordoni R, Yazbeck V, et al. Phase 2 study of frontline brentuximab vedotin plus nivolumab in patients with Hodgkin lymphoma aged ≥60 years. Blood. 2019;134(Supplement_1):237. doi:10.1182/blood-2019-124866
   Google Scholar
• Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021;138(6):427–438. doi:10.1182/blood.2020009178
   PubMed Web of Science ®Google Scholar
• Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm Phase II CheckMate 205 trial. JCO. 2018;36(14):1428–1439. doi:10.1200/JCO.2017.76.0793
   PubMed Web of Science ®Google Scholar
• Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front Pharmacol. 2022;13:868695. doi:10.3389/fphar.2022.868695
   PubMed Web of Science ®Google Scholar
• Klein BA, Shazib MA, Villa A, et al. Immune checkpoint inhibitors in cancer therapy: review of orofacial adverse events and role of the oral healthcare provider. Front Oral Health. 2022;3:968157. doi:10.3389/froh.2022.968157
   Google Scholar
• Choi J, Lee SY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 2020;20(1):e9. doi:10.4110/in.2020.20.e9
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563–580. doi:10.1038/s41571-019-0218-0
   PubMed Web of Science ®Google Scholar
• Hakim NN, Chi J, Olazagasti C, Liu JM. Secondary hemophagocytic lymphohistiocytosis versus cytokine release syndrome in severe COVID-19 patients. Exp Biol Med. 2021;246(1):5–9. doi:10.1177/1535370220962043
   Web of Science ®Google Scholar
• Grewal US, Thotamgari SR, Shah PR, et al. Hematological immune related adverse events after treatment with immune checkpoint inhibitors: immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis. Eur J Cancer. 2021;153:270–271. doi:10.1016/j.ejca.2021.04.046
   Web of Science ®Google Scholar
• Noseda R, Bertoli R, Müller L, et al. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports. J Immunother Cancer. 2019;7:117. doi:10.1186/s40425-019-0598-9
   PubMed Web of Science ®Google Scholar
• Dupré A, Michot J, Schoeffler A, et al. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review. Br J Haematol. 2020;189(5):985–992. doi:10.1111/bjh.16630
   Web of Science ®Google Scholar
• Liu LL, Skribek M, Harmenberg U, et al. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature. J Immunother Cancer. 2023;11(3):e005841. doi:10.1136/jitc-2022-005841
   Web of Science ®Google Scholar
• Diefenbach CSM, Leonard JP. Targeting CD30 in Hodgkin lymphoma: antibody-drug conjugates make a difference. Am Soc Clin Oncol Educat Book. 2012;32:162–166. doi:10.14694/EdBook_AM.2012.32.83
   Google Scholar
• Horwitz S, O’Connor OA, Pro B, et al. The ECHELON-2 Trial: 5-year results of a randomized, Phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288–298. doi:10.1016/j.annonc.2021.12.002
   PubMed Web of Science ®Google Scholar
• Alig SK, Dreyling M, Seppi B, et al. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (s ALCL): a case report and review of literature. Eur J Haematol. 2015;94(6):554–557. doi:10.1111/ejh.12396
   PubMed Web of Science ®Google Scholar
• Qlik sense FDA Adverse Events Reporting System (FAERS) Public Dashboard - Brentuximab Vedotin. Available from: https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/45beeb74-30ab-46be-8267-5756582633b4/state/analysis. Accessed May 2, 2023.
   Google Scholar
• Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. doi:10.1186/s40425-018-0343-9
   PubMed Web of Science ®Google Scholar
• Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel t cell-engaging therapies. Cancer J. 2014;20(2):119–122. doi:10.1097/PPO.0000000000000035
   PubMed Web of Science ®Google Scholar
• Hines M, Bhatt N, Talano JAM. Diagnosis, treatment, and management of hemophagocytic lymphohistiocytosis in the critical care unit. Criti Care Pediat Immunocomp Hematol. 2018;159–182. doi:10.1007/978-3-030-01322-6_9
   Google Scholar
• La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465–2477. doi:10.1182/blood.2018894618
   PubMed Web of Science ®Google Scholar
• Thakkar K, Khurana S, Sun Y, Hembree TN. Diabetic ketoacidosis and profound insulin resistance from brentuximab vedotin. Cureus. 2023. doi:10.7759/cureus.35804
   Web of Science ®Google Scholar
• Quintas Joseph B, Mowatt KB, Mullally JA, et al. New onset persistent hyperglycemia with initiation of brentuximab treatment. Blood. 2021;138(Supplement 1):4540. doi:10.1182/blood-2021-148864
   Google Scholar
• Tama E, Black M, Moustafa MA, Hurtado MD. Severe insulin resistance in a patient treated with nivolumab and brentuximab-vedotin for Hodgkin lymphoma. JCEM Case Rep. 2023;1(6):luad121. doi:10.1210/jcemcr/luad121
   Google Scholar